David Vizarraga

David Vizarraga

Auto-generated profile, based on publicly available information

David Vizarraga

Instituto de Biología Molecular de Barcelona (IBMB-CSIC), Parc Científic de Barcelona, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
DVDavid Vizarraga
David Vizarraga
AKAkihiro Kawamoto
Akihiro Kawamoto
UMU. Matsumoto
U. Matsumoto
RIRamiro Illanes
Ramiro Illanes
RPRosa Pérez-Luque
Rosa Pérez-Luque
DADavid Aparicio
David Aparicio
Mycoplasma pneumoniae is a bacterial human pathogen that causes primary atypical pneumonia. M. pneumoniae motility and infectivity are mediated by the immunodominant proteins P1 and P40/P90, which form a transmembrane adhesion complex. Here we report the structure of P1, determined by X-ray crystallography and cryo-electron microscopy, and the X-ray structure of P40/P90. Contrary to what had been suggested, the binding site for sialic acid was found in P40/P90 and not in P1. Genetic and clinical variability concentrates on the N-terminal domain surfaces of P1 and P40/P90. Polyclonal antibodies generated against the mostly conserved C-terminal domain of P1 inhibited adhesion of M. pneumoniae, and serology assays with sera from infected patients were positive when tested against this C-terminal domain. P40/P90 also showed strong reactivity against human infected sera. The architectural elements determined for P1 and P40/P90 open new possibilities in vaccine development against M. pneumoniae infections.

13 February 2023 in Nature Structural & Molecular Biology
Verified
Journal Article
Open access
PDF file
LSLasse Sprankel
Lasse Sprankel
DVDavid Vizarraga
David Vizarraga
JMJesús Martín
Jesús Martín
SMSina Manger
Sina Manger
JMJakob Meier-Credo
Jakob Meier-Credo
AFAchilleas S. Frangakis
Achilleas S. Frangakis
Mycoplasma pneumoniae, responsible for approximately 30% of community-acquired human pneumonia, needs to extract lipids from the host environment for survival and proliferation. Here, we report a comprehensive structural and functional analysis of the previously uncharacterized protein P116 (MPN_213). Single-particle cryo-electron microscopy of P116 reveals a homodimer presenting a previously unseen fold, forming a huge hydrophobic cavity, which is fully accessible to solvent. Lipidomics analysis shows that P116 specifically extracts lipids such as phosphatidylcholine, sphingomyelin and cholesterol. Structures of different conformational states reveal the mechanism by which lipids are extracted. This finding immediately suggests a way to control Mycoplasma infection by interfering with lipid uptake.

16 July 2025 in Protein Science
Verified
Journal Article
Open access
DCDamiano Cianferoni
Damiano Cianferoni
DVDavid Vizarraga
David Vizarraga
AFAna María Fernández‐Escamilla
Ana María Fernández‐Escamilla
IFIgnacio Fita
Ignacio Fita
RHRahma Hamdani
Rahma Hamdani
LSLuis Serrano
Luis Serrano
Since AlphaFold2's rise, many deep learning methods for protein design have emerged. Here, we validate widely used and recognized tools, compare them with first‐principle methods, and explore their combinations, focusing on their effectiveness in protein redesign and potential for therapeutic repurposing. We address two challenges: evaluating tools and combinations ability to detect the effects of multiple concurrent mutations in protein variants, and leveraging large‐scale datasets to compare modeling‐free methods, namely force fields, which handle point mutations well with limited backbone rearrangement, and inverse folding tools, which excel at native sequence recovery but may struggle with non‐natural proteins. Debuting TriCombine, a tool that identifies residue triangles in input structures, matches them to a structural database, and scores mutants based on substitution frequencies, we shortlisted candidates, modeled them with FoldX, and generated 16 SH3 mutants carrying up to 9 concurrent substitutions. The dataset was expanded to include 36 mutants and 11 crystal structures (7 newly solved), along with a parallel set of multiple non‐concurrent mutants from three additional proteins. For broader validation, we analyzed 160,000 four‐site GB1 mutants and 163,555 (single and double) variants across 179 natural and de novo domains. We show that combining AI‐based modeling tools with force field scoring functions yields the most reliable results. Inverse folding tools perform very well but lose accuracy on less‐represented proteins. First‐principle force fields like FoldX remain the most accurate for point mutations. All methods perform worse when applied to unsolved de novo models, underscoring the need for hybrid strategies in robust protein design.

16 December 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
DVDavid Vizarraga
David Vizarraga
MMMarina Marcos
Marina Marcos
NVNoemi Rotllan Vila
Noemi Rotllan Vila
JMJesús Martín
Jesús Martín
DSDavid Santos
David Santos
Joan Carles Escolà-GilJoan Carles Escolà-Gil
Joan Carles Escolà-Gil
Mycoplasma pneumoniae (MPN) is a bacterial pathogen that primarily causes atypical pneumonia. It cannot synthesize certain essential lipids and therefore relies on the host for their acquisition to survive. MPN has been detected in increased amounts within ruptured atherosclerotic plaques. In this work, we show that the protein P116 facilitates cholesterol acquisition from LDL, HDL and various cell types. Targeting P116’s C-terminal domain with a monoclonal antibody inhibits cholesterol acquisition and bacterial growth in vitro. Phase contrast epifluorescence microscopy of human arteries reveals that this antibody blocks MPN binding to atherosclerotic lesions ex vivo. Additionally, an MPN chassis injected into hyperlipidemic female mice localizes to the liver and atherosclerotic plaques. Here, we report that P116 plays a role in extracting essential lipids from lipoproteins and host cells and regulates MPN localization to atheromatous plaques. The study highlights MPN’s potential as a tool for targeting atherosclerotic lesions and fatty liver.

8 January 2025 in Research Square
Verified
Preprint
Open access
PDF file
Joan Carles Escolà-GilJoan Carles Escolà-Gil
Joan Carles Escolà-Gil
DVDavid Vizarraga
David Vizarraga
MMMarina Marcos-Silva
Marina Marcos-Silva
NVNoemi Rotllan Vila
Noemi Rotllan Vila
JMJesús Martín
Jesús Martín
IFIgnacio Fita
Ignacio Fita
Mycoplasma pneumoniae ( MPN ) is a bacterial pathogen in humans that primarily causes atypical pneumonia. MPN cannot synthesize several lipids crucial for its cell membrane structure and needs to extract them from the lung of the host to survive. The protein responsible for extracting essential lipids from cell membranes is P116. MPN has been detected in increased quantities within ruptured atherosclerotic plaques and the question is how MPN survives in the blood and in the plaques and obtains the lipids necessary for its membrane. Here we show that P116 can uptake essential lipids from LDL and HDL and when targeting its C-terminal domain via a monoclonal antibody there is growth inhibition in vitro . Phase contrast epifluorescence microscopy of human arteries also revealed that this antibody blocks MPN binding to human atherosclerotic lesions ex vivo . Furthermore, injection of MPN in the blood results in accumulation of MPN within the liver and atheroma plaques in a hyperlipidemic mouse model. We conclude that P116 plays a critical role in extracting essential lipids from physiological circulating lipoproteins and from host cells and regulates MPN localization to liver and atheromatous plaques. These results suggest new strategies for managing mycoplasma infections and addressing the potential complications of MPN infections in atherosclerotic lesions. They also open avenues for utilizing biotechnological tools in the treatment of atherosclerotic and hepatic lesions.

15 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
DCDamiano Cianferoni
Damiano Cianferoni
DRDavid Vizarraga Revuelto
David Vizarraga Revuelto
AEAna Maria Fernandez Escamilla
Ana Maria Fernandez Escamilla
IFIgnacio Fita
Ignacio Fita
RHRahma Hamdani
Rahma Hamdani
LPLuis Serrano Pubul
Luis Serrano Pubul
Since AlphaFold2's rise, many deep learning methods for protein design have emerged. Here, we validate widely used and recognized tools, compare them with first-principle methods, and explore their combinations, focusing on their effectiveness in protein redesign and potential for therapeutic repurposing. We address two challenges: evaluating tools and combinations ability to detect the effects of multiple concurrent mutations in protein variants, and leveraging large-scale datasets to compare modeling-free methods, namely force fields, which handle point mutations well with limited backbone rearrangement, and inverse folding tools, which excel at native sequence recovery but may struggle with non-natural proteins. Debuting TriCombine, a tool that identifies residue triangles in input structures, matches them to a structural database, and scores mutants based on substitution frequencies, we shortlisted candidates, modeled them with FoldX, and generated 16 SH3 mutants carrying up to 9 concurrent substitutions. The dataset was expanded to include 36 mutants and 11 crystal structures (7 newly solved), along with a parallel set of multiple non-concurrent mutants from three additional proteins. For broader validation, we analyzed 160,000 four-site GB1 mutants and 163,555 (single and double) variants across 179 natural and de novo domains. We show that combining AI-based modeling tools with force field scoring functions yields the most reliable results. Inverse folding tools perform very well but lose accuracy on less-represented proteins. First-principle force fields like FoldX remain the most accurate for point mutations. All methods perform worse when applied to unsolved de novo models, underscoring the need for hybrid strategies in robust protein design.